Biohaven reports another trial failure for troriluzole; Cyclica raises C$23M for AI driven discovery platform
→ Four months after Biohaven $BHVN reported that troriluzole flopped in a study for anxiety, the biotech is back with another setback to report. The therapy has now also failed at treating obsessive-compulsive disorder, though the execs in charge still see plenty of good reasons for forging ahead into a pivotal trial.
“Although the p-value in this proof of concept study did not reach statistical significance at the primary Y-BOCS endpoint at week 12,” the biotech noted in a statement, “the results reveal a consistent treatment benefit of troriluzole over time and provide the appropriate data to power future studies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
